Nuala Moran

It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.

With investors keeping their money in their pockets, and the IPO window nailed shut, the 33 year-old model of biotech funding is outdated, says a new report.

The EU doesn’t do fundamental research, which is why it has taken 20 years for researchers involved in high risk research to get together, but it can’t get by without it.

Can anybody spare a dime for science? With the usual funding avenues blocked development-stage companies are turning to research charities.

The European Commission is to boost funding for high-risk futuristic research in ICT, to provide foundations for economic recovery and future competitiveness.

As governments direct stimulus packages towards science and research, don’t forget the current crop of spin-outs who face extinction in a frozen capital market, writes Nuala Moran.

The precarious position of the UK’s life sciences sector is underlined by fundraising failures among 295 of its members.

In a new five-year plan to create jobs and rebuild the country’s industrial base, the Irish government has given science a leading role in revitalising the Irish economy.

Beyond its blockbuster drugs Genentech has a commodity rare in a large company – an entrepreneurial culture. Can Roche preserve this?

Putting public money into VC seed funds has yielded a large crop of cash-hungry UK start-ups. But with funding proving hard to find, who will feed them now?